Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database
Conclusions: This study suggests that the early signs and symptoms of potential fatal heart failure should be monitored during carfilzomib treatment.Oncology (Source: Oncology)
Source: Oncology - October 21, 2021 Category: Cancer & Oncology Source Type: research

A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results
CONCLUSION: Initial results of this new biomarker panel (quintuple-wildtype) are promising for anti-EGFR therapy with cetuximab plus doublet chemotherapy (FOLFIRI) in first-line treatment of metastatic CRC. These results warrant confirmation with higher case numbers in the IVOPAK II trial.PMID:34670215 | DOI:10.1159/000519252 (Source: Oncology)
Source: Oncology - October 20, 2021 Category: Cancer & Oncology Authors: Axel Wein Robert Stoehr Stephan Kersting J ürgen Siebler Susanne Merkel Dagmar Busse Kerstin Wolff Nicola Ostermeier Clemens Neufert Francesco Vitali Markus Eckstein Jan-Peter Roth Peter Anhut Waldemar Schreiner Michael Uder Arndt Hartmann Markus F Neura Source Type: research

A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results
CONCLUSION: Initial results of this new biomarker panel (quintuple-wildtype) are promising for anti-EGFR therapy with cetuximab plus doublet chemotherapy (FOLFIRI) in first-line treatment of metastatic CRC. These results warrant confirmation with higher case numbers in the IVOPAK II trial.PMID:34670215 | DOI:10.1159/000519252 (Source: Oncology)
Source: Oncology - October 20, 2021 Category: Cancer & Oncology Authors: Axel Wein Robert Stoehr Stephan Kersting J ürgen Siebler Susanne Merkel Dagmar Busse Kerstin Wolff Nicola Ostermeier Clemens Neufert Francesco Vitali Markus Eckstein Jan-Peter Roth Peter Anhut Waldemar Schreiner Michael Uder Arndt Hartmann Markus F Neura Source Type: research

A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results
CONCLUSION: Initial results of this new biomarker panel (quintuple-wildtype) are promising for anti-EGFR therapy with cetuximab plus doublet chemotherapy (FOLFIRI) in first-line treatment of metastatic CRC. These results warrant confirmation with higher case numbers in the IVOPAK II trial.PMID:34670215 | DOI:10.1159/000519252 (Source: Oncology)
Source: Oncology - October 20, 2021 Category: Cancer & Oncology Authors: Axel Wein Robert Stoehr Stephan Kersting J ürgen Siebler Susanne Merkel Dagmar Busse Kerstin Wolff Nicola Ostermeier Clemens Neufert Francesco Vitali Markus Eckstein Jan-Peter Roth Peter Anhut Waldemar Schreiner Michael Uder Arndt Hartmann Markus F Neura Source Type: research

A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI – Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results
Conclusion: Initial results of this new biomarker panel (quintuple-wildtype) are promising for anti-EGFR therapy with cetuximab plus doublet chemotherapy (FOLFIRI) in first-line treatment of metastatic CRC. These results warrant confirmation with higher case numbers in the IVOPAK II trial.Oncology (Source: Oncology)
Source: Oncology - October 20, 2021 Category: Cancer & Oncology Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
CONCLUSIONS: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.PMID:34583356 | DOI:10.1159/000515951 (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Authors: Umberto Basso Giuseppe Procopio Giuseppe Fornarini Francesco Massari Alessandra Bearz Lucia Fratino Michele Milella Maria Bassanelli Paola Ermacora Davide Bimbatti Elena Verzoni Mimma Rizzo Camillo Porta Source Type: research

Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
Conclusions: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.Oncology (Source: Oncology)
Source: Oncology - September 28, 2021 Category: Cancer & Oncology Source Type: research

Serum Matrix Metalloproteinase-8 and Myeloperoxidase Predict Survival after Resection of Colorectal Liver Metastases
CONCLUSIONS: Pre- and postoperatively high MMP-8 associates with worse 10-year OS, and postoperatively high MPO associates with better 5-year DFS. CEA, CA19-9, and CRP are also prognostic.PMID:34571507 | DOI:10.1159/000518955 (Source: Oncology)
Source: Oncology - September 27, 2021 Category: Cancer & Oncology Authors: Pauliina Reijonen Reetta Peltonen Taina Tervahartiala Timo Sorsa Helena Isoniemi Source Type: research

Serum Matrix Metalloproteinase-8 and Myeloperoxidase Predict Survival after Resection of Colorectal Liver Metastases
CONCLUSIONS: Pre- and postoperatively high MMP-8 associates with worse 10-year OS, and postoperatively high MPO associates with better 5-year DFS. CEA, CA19-9, and CRP are also prognostic.PMID:34571507 | DOI:10.1159/000518955 (Source: Oncology)
Source: Oncology - September 27, 2021 Category: Cancer & Oncology Authors: Pauliina Reijonen Reetta Peltonen Taina Tervahartiala Timo Sorsa Helena Isoniemi Source Type: research

Serum Matrix Metalloproteinase-8 and Myeloperoxidase Predict Survival after Resection of Colorectal Liver Metastases
Conclusions: Pre- and postoperatively high MMP-8 associates with worse 10-year OS, and postoperatively high MPO associates with better 5-year DFS. CEA, CA19-9, and CRP are also prognostic.Oncology (Source: Oncology)
Source: Oncology - September 27, 2021 Category: Cancer & Oncology Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Oncology. 2021 Sep 14:1-10. doi: 10.1159/000517490. Online ahead of print.ABSTRACTINTRODUCTION: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.MATERIAL AND METHODS: Data from all patients treated at the University Hospital Ulm for EBC between January 2013 and December 2015 with documented results for internal Ki67 assessment of the primary (n = 917) tumor were retrospectively analyzed evaluating the associations between Ki67 and other clinicopathological factors.RESULTS: 595 (64.9%) patients had a Ki67
Source: Oncology - September 18, 2021 Category: Cancer & Oncology Authors: Amelie de Gregorio Thomas Wolfram Paul Friedl Eva Hering Peter Widschwendter Nikolaus de Gregorio Inga Bekes Wolfgang Janni Davut Dayan Jens Bodo Huober Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Oncology. 2021 Sep 8:1-10. doi: 10.1159/000518612. Online ahead of print.ABSTRACTBackground & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of progression to an advanced stage.METHODS: We enrolled and retrospectively examined 289 patients with Child-Pugh class A who had been diagnosed with intermediate-stage HCC and underwent initial trans-arterial chemoembolization (TACE). Patients were...
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Authors: Shigeo Shimose Hideki Iwamoto Masatoshi Tanaka Takashi Niizeki Tomotake Shirono Akira Kajiwara Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Ryoko Kuromatsu Takumi Kawaguchi Hironori Koga Takuji Torimura Source Type: research

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
Conclusion: This analysis described Ki67 in different subtypes in EBC and its association with clinicopathological factors. According to more aggressive tumor biology, the respective subgroups also showed higher median Ki67 levels. However, definition of low and high proliferation index itself is difficult. It is essential to interpret Ki67 indices carefully with regard to the own institutional values and other clinicopathological factors.Oncology (Source: Oncology)
Source: Oncology - September 14, 2021 Category: Cancer & Oncology Source Type: research

Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study
CONCLUSIONS: Lenvatinib shows no significant difference in response between patients with and without viral infection. Treatment strategies based on the etiology of liver disease may lead to good clinical outcome.PMID:34515171 | DOI:10.1159/000517494 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Takeshi Hatanaka Satoru Kakizaki Tamon Nagashima Masashi Namikawa Takashi Ueno Hiroki Tojima Daichi Takizawa Atsushi Naganuma Hirotaka Arai Norifumi Harimoto Ken Shirabe Toshio Uraoka Source Type: research

Survival Time among Young and Old Breast Cancer Patients in Relation to Circulating Blood-Based Biomarkers, Acute Radiation Skin Reactions, and Tumour Recurrence
Oncology. 2021 Sep 3:1-7. doi: 10.1159/000518184. Online ahead of print.ABSTRACTINTRODUCTION: It has been suggested that age could influence the treatment-induced side effects and survival time of cancer patients. The influence of age on blood-based biomarkers, acute radiation skin reactions (ARSRs), and survival time of breast cancer patients was analysed.MATERIALS AND METHODS: Two hundred ninety-three individuals, 119 breast cancer patients, and 174 healthy blood donors were included.RESULTS: Before radiotherapy (RT), decreased levels of lymphocytes, interleukin 2, platelet-derived growth factors, and tumour necrosis fac...
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Nongnit Laytragoon Lewin Delmy Oliva Mats Nilsson Bengt- Åke Andersson Sture L öfgren Freddi Lewin Source Type: research

The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer
CONCLUSION: The impact of exogenous estrogen exposure on ER-positive, HER2-negative early breast cancer characteristics is limited. In the long term, none of the evaluated exposures had negative effect on DFS and OS.PMID:34515186 | DOI:10.1159/000518183 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Orly Yariv Raz Mutai Ofer Rotem Daliah Tsoref Yasmin Korzets Assaf Moore Tzippy Shochat Rinat Yerushalmi Hadar Goldvaser Source Type: research

Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer
CONCLUSION: GS chemotherapy after curative surgery was well tolerated, showed better clinical benefit in the adjuvant setting, and can effectively reduce BTC recurrence.PMID:34515195 | DOI:10.1159/000518094 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Kiyotaka Hosoda Kentaro Fukushima Akira Shimizu Hiroaki Motoyama Koji Kubota Tsuyoshi Notake Shinsuke Sugenoya Hikaru Hayashi Koya Yasukawa Ryoichiro Kobayashi Yuji Soejima Source Type: research

Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study
CONCLUSION: IRI2 might be a reasonable option for heavily pretreated patients with mCRC who achieved disease control with prior irinotecan therapy.PMID:34515197 | DOI:10.1159/000518041 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Moon Ki Choi Yongjun Cha Ji Yeon Baek Source Type: research

The What, the Why, and the How of Liver Ablations: A Practical Guide for the Medical Oncologist
This article provides a broad overview of the most commonly used ablation techniques and highlights the most relevant technical aspects such as the ideal setting in the operating theatre; which image-guided methods are available, including the growing application of fusion imaging; or contrast-enhanced ultrasound for guiding/monitoring the procedure. A further aim is to expand the knowledge among medical oncologists about liver ablation procedures and to provide insights into the future perspectives of percutaneous minimally invasive procedures in the liver.PMID:34515198 | DOI:10.1159/000518358 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Nicol ò Gennaro Simone Schiaffino Giovanni Mauri Lorenzo Monfardini Source Type: research

Perioperative Immune Checkpoint Inhibitors in Renal Cell and Urothelial Carcinomas: An Exciting New Paradigm under Investigation?
Oncology. 2021 Sep 8:1-5. doi: 10.1159/000518741. Online ahead of print.NO ABSTRACTPMID:34515202 | DOI:10.1159/000518741 (Source: Oncology)
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Carlo Buonerba Petros Grivas Giuseppe Di Lorenzo Source Type: research

The Relationship between the Tissue Expression of TLR2, TLR4, TLR5, and TLR7 and Systemic Inflammatory Responses in Colorectal Cancer Patients
Oncology. 2021 Sep 8:1-12. doi: 10.1159/000518397. Online ahead of print.ABSTRACTBACKGROUND: Colorectal cancer (CRC) is the third most commonly diagnosed malignancy globally. CRC patients with elevated plasma C-reactive protein (CRP) levels exhibit compromised prognoses. Toll-like receptors (TLRs), activating the innate and adaptive immune systems, may contribute to pro- and antitumorigenic inflammatory responses. We aimed to identify a possible link between local and systemic inflammatory responses in CRC patients by investigating the association between tissue TLRs and plasma CRP.METHODS: Tissue expressions of TLR2, TLR4...
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Ines Beilmann-Lehtonen Jaana Hagstr öm Tuomas Kaprio Ulf-H åkan Stenman Karin Strig ård Richard Palmqvist Ulf Gunnarsson Camilla B öckelman Caj Haglund Source Type: research

Toward a Platform for Structured Data Acquisition in Oncology: A Pilot Study on Prostate Cancer Screening
Oncology. 2021 Aug 31:1-11. doi: 10.1159/000518381. Online ahead of print.ABSTRACTINTRODUCTION: Physicians spend an ever-rising amount of time to collect relevant information from highly variable medical reports and integrate them into the patient's health condition.OBJECTIVES: We compared synoptic reporting based on data elements to narrative reporting in order to evaluate its capabilities to collect and integrate clinical information.METHODS: We developed a novel system to align medical reporting to data integration requirements and tested it in prostate cancer screening. We compared expenditure of time, data quality, an...
Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Maurice Henkel Kirsten D Mertz Jonas Laux Matthias Klan Christian Breit Katharina Marston Marc O Matthias Sarah G Dugas Sebastian Manneck Bram Stieltjes Helge Seifert Christian Wetterauer Source Type: research

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Conclusion: The administration of MTAs in patients with intermediate-stage HCC contributes to the prevention of stage progression and prolongs OS.Oncology (Source: Oncology)
Source: Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

The Relationship between the Tissue Expression of TLR2, TLR4, TLR5, and TLR7 and Systemic Inflammatory Responses in Colorectal Cancer Patients
Conclusions: High tissue TLR2, TLR5, and TLR7 levels were associated with a better prognosis. Among low-CRP patients, those with high TLR2, TLR5, and TLR7 immunoexpressions exhibited a better prognosis. Among high CRP patients, a high TLR4 immunoexpression was associated with a better prognosis.Oncology (Source: Oncology)
Source: Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research

Perioperative Immune Checkpoint Inhibitors in Renal Cell and Urothelial Carcinomas: An Exciting New Paradigm under Investigation?
Oncology (Source: Oncology)
Source: Oncology - September 8, 2021 Category: Cancer & Oncology Source Type: research